Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) Stock Competitors & Peer Comparison
See 2526.HK's competitors and their performance on the HKSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for 2526.HK and its HKSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2526.HK | HK$429.60 | +4.78% | 38.4B | -490.91 | -HK$0.88 | N/A |
| 2252.HK | HK$21.18 | +0.00% | 21.7B | -174.77 | -HK$0.12 | N/A |
| 0853.HK | HK$6.08 | +0.00% | 11.6B | 31.69 | HK$0.19 | N/A |
| 2675.HK | HK$35.34 | +4.12% | 11.2B | -132.69 | -HK$0.26 | N/A |
| 2697.HK | HK$294.60 | +4.91% | 10.1B | -103.74 | -HK$2.74 | N/A |
| 3600.HK | HK$8.14 | +4.69% | 7.4B | 10.84 | HK$0.73 | +3.66% |
| 2190.HK | HK$20.70 | +0.29% | 6.4B | 19.10 | HK$1.08 | +1.75% |
| 6606.HK | HK$14.14 | +0.00% | 6.3B | 25.05 | HK$0.56 | N/A |
| 1302.HK | HK$1.38 | +0.00% | 5.8B | 98.95 | HK$0.01 | N/A |
| 1789.HK | HK$4.91 | +1.45% | 5.2B | 12.73 | HK$0.38 | +2.43% |
Stock Comparison
Shanghai MicroPort MedBot (Group) Co., Ltd. (HKSE: 2252.HK)
2526.HK vs 2252.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2252.HK has a market cap of 21.7B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2252.HK trades at HK$21.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2252.HK's P/E ratio is -174.77. In terms of profitability, 2526.HK's ROE is N/A, compared to 2252.HK's ROE of -0.53%. Regarding short-term risk, 2526.HK is less volatile compared to 2252.HK. This indicates lower risk in terms of short-term price fluctuations for 2526.HK.Check 2252.HK's competition here
MicroPort Scientific Corp. (HKSE: 0853.HK)
2526.HK vs 0853.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 0853.HK has a market cap of 11.6B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 0853.HK trades at HK$6.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 0853.HK's P/E ratio is 31.69. In terms of profitability, 2526.HK's ROE is N/A, compared to 0853.HK's ROE of +0.06%. Regarding short-term risk, 2526.HK is more volatile compared to 0853.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 0853.HK's competition here
Shenzhen Edge Medical Co Ltd (HKSE: 2675.HK)
2526.HK vs 2675.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2675.HK has a market cap of 11.2B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2675.HK trades at HK$35.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2675.HK's P/E ratio is -132.69. In terms of profitability, 2526.HK's ROE is N/A, compared to 2675.HK's ROE of N/A. Regarding short-term risk, 2526.HK is less volatile compared to 2675.HK. This indicates lower risk in terms of short-term price fluctuations for 2526.HK.Check 2675.HK's competition here
Guangdong True Health Medical Technology Development Co., Ltd. (HKSE: 2697.HK)
2526.HK vs 2697.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2697.HK has a market cap of 10.1B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2697.HK trades at HK$294.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2697.HK's P/E ratio is -103.74. In terms of profitability, 2526.HK's ROE is N/A, compared to 2697.HK's ROE of N/A. Regarding short-term risk, 2526.HK is more volatile compared to 2697.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 2697.HK's competition here
Modern Dental Group Limited (HKSE: 3600.HK)
2526.HK vs 3600.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 3600.HK has a market cap of 7.4B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 3600.HK trades at HK$8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 3600.HK's P/E ratio is 10.84. In terms of profitability, 2526.HK's ROE is N/A, compared to 3600.HK's ROE of +0.20%. Regarding short-term risk, 2526.HK is more volatile compared to 3600.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 3600.HK's competition here
Zylox-Tonbridge Medical Technology Co., Ltd. (HKSE: 2190.HK)
2526.HK vs 2190.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2190.HK has a market cap of 6.4B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2190.HK trades at HK$20.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2190.HK's P/E ratio is 19.10. In terms of profitability, 2526.HK's ROE is N/A, compared to 2190.HK's ROE of +0.10%. Regarding short-term risk, 2526.HK is more volatile compared to 2190.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 2190.HK's competition here
New Horizon Health Limited (HKSE: 6606.HK)
2526.HK vs 6606.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 6606.HK has a market cap of 6.3B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 6606.HK trades at HK$14.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 6606.HK's P/E ratio is 25.05. In terms of profitability, 2526.HK's ROE is N/A, compared to 6606.HK's ROE of -0.04%. Regarding short-term risk, 2526.HK is less volatile compared to 6606.HK. This indicates lower risk in terms of short-term price fluctuations for 2526.HK.Check 6606.HK's competition here
LifeTech Scientific Corporation (HKSE: 1302.HK)
2526.HK vs 1302.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 1302.HK has a market cap of 5.8B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 1302.HK trades at HK$1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 1302.HK's P/E ratio is 98.95. In terms of profitability, 2526.HK's ROE is N/A, compared to 1302.HK's ROE of +0.02%. Regarding short-term risk, 2526.HK is more volatile compared to 1302.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 1302.HK's competition here
AK Medical Holdings Limited (HKSE: 1789.HK)
2526.HK vs 1789.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 1789.HK has a market cap of 5.2B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 1789.HK trades at HK$4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 1789.HK's P/E ratio is 12.73. In terms of profitability, 2526.HK's ROE is N/A, compared to 1789.HK's ROE of +0.13%. Regarding short-term risk, 2526.HK is more volatile compared to 1789.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 1789.HK's competition here
Star Sports Medicine Co., Ltd. (HKSE: 1609.HK)
2526.HK vs 1609.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 1609.HK has a market cap of 4.7B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 1609.HK trades at HK$116.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 1609.HK's P/E ratio is 35.40. In terms of profitability, 2526.HK's ROE is N/A, compared to 1609.HK's ROE of N/A. Regarding short-term risk, 2526.HK is less volatile compared to 1609.HK. This indicates lower risk in terms of short-term price fluctuations for 2526.HK.Check 1609.HK's competition here
MicroPort NeuroTech Limited (HKSE: 2172.HK)
2526.HK vs 2172.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2172.HK has a market cap of 4.7B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2172.HK trades at HK$8.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2172.HK's P/E ratio is 22.80. In terms of profitability, 2526.HK's ROE is N/A, compared to 2172.HK's ROE of +0.10%. Regarding short-term risk, 2526.HK is more volatile compared to 2172.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 2172.HK's competition here
China Isotope & Radiation Corporation (HKSE: 1763.HK)
2526.HK vs 1763.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 1763.HK has a market cap of 4.6B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 1763.HK trades at HK$13.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 1763.HK's P/E ratio is 13.06. In terms of profitability, 2526.HK's ROE is N/A, compared to 1763.HK's ROE of +0.06%. Regarding short-term risk, 2526.HK is more volatile compared to 1763.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 1763.HK's competition here
Beijing Chunlizhengda Medical Instruments Co., Ltd. (HKSE: 1858.HK)
2526.HK vs 1858.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 1858.HK has a market cap of 4.5B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 1858.HK trades at HK$7.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 1858.HK's P/E ratio is 9.65. In terms of profitability, 2526.HK's ROE is N/A, compared to 1858.HK's ROE of +0.09%. Regarding short-term risk, 2526.HK is more volatile compared to 1858.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 1858.HK's competition here
Medcaptain Medical Technology Co. Ltd. Class H (HKSE: 2041.HK)
2526.HK vs 2041.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2041.HK has a market cap of 4B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2041.HK trades at HK$8.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2041.HK's P/E ratio is N/A. In terms of profitability, 2526.HK's ROE is N/A, compared to 2041.HK's ROE of N/A. Regarding short-term risk, 2526.HK is more volatile compared to 2041.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 2041.HK's competition here
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (HKSE: 2291.HK)
2526.HK vs 2291.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2291.HK has a market cap of 3.7B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2291.HK trades at HK$11.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2291.HK's P/E ratio is 15.86. In terms of profitability, 2526.HK's ROE is N/A, compared to 2291.HK's ROE of +0.10%. Regarding short-term risk, 2526.HK is more volatile compared to 2291.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 2291.HK's competition here
Peijia Medical Limited (HKSE: 9996.HK)
2526.HK vs 9996.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 9996.HK has a market cap of 3.2B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 9996.HK trades at HK$5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 9996.HK's P/E ratio is -20.53. In terms of profitability, 2526.HK's ROE is N/A, compared to 9996.HK's ROE of -0.08%. Regarding short-term risk, 2526.HK is more volatile compared to 9996.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 9996.HK's competition here
MicroTech Medical (Hangzhou) Co., Ltd. (HKSE: 2235.HK)
2526.HK vs 2235.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2235.HK has a market cap of 2.9B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2235.HK trades at HK$6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2235.HK's P/E ratio is 30.83. In terms of profitability, 2526.HK's ROE is N/A, compared to 2235.HK's ROE of +0.04%. Regarding short-term risk, 2526.HK is more volatile compared to 2235.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 2235.HK's competition here
Shanghai HeartCare Medical Technology Corporation Limited (HKSE: 6609.HK)
2526.HK vs 6609.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 6609.HK has a market cap of 2B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 6609.HK trades at HK$53.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 6609.HK's P/E ratio is 332.30. In terms of profitability, 2526.HK's ROE is N/A, compared to 6609.HK's ROE of +0.08%. Regarding short-term risk, 2526.HK is more volatile compared to 6609.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 6609.HK's competition here
Acotec Scientific Holdings Limited (HKSE: 6669.HK)
2526.HK vs 6669.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 6669.HK has a market cap of 1.8B. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 6669.HK trades at HK$6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 6669.HK's P/E ratio is 9.21. In terms of profitability, 2526.HK's ROE is N/A, compared to 6669.HK's ROE of -0.03%. Regarding short-term risk, 2526.HK is more volatile compared to 6669.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 6669.HK's competition here
Sisram Medical Ltd (HKSE: 1696.HK)
2526.HK vs 1696.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 1696.HK has a market cap of 920.3M. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 1696.HK trades at HK$1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 1696.HK's P/E ratio is 6.21. In terms of profitability, 2526.HK's ROE is N/A, compared to 1696.HK's ROE of +0.02%. Regarding short-term risk, 2526.HK is more volatile compared to 1696.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 1696.HK's competition here
Gaush Meditech Ltd (HKSE: 2407.HK)
2526.HK vs 2407.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2407.HK has a market cap of 680.3M. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2407.HK trades at HK$4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2407.HK's P/E ratio is 7.88. In terms of profitability, 2526.HK's ROE is N/A, compared to 2407.HK's ROE of +0.05%. Regarding short-term risk, 2526.HK is more volatile compared to 2407.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 2407.HK's competition here
MicroPort CardioFlow Medtech Corporation (HKSE: 2160.HK)
2526.HK vs 2160.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2160.HK has a market cap of 629.5M. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2160.HK trades at HK$1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2160.HK's P/E ratio is 117.11. In terms of profitability, 2526.HK's ROE is N/A, compared to 2160.HK's ROE of -0.07%. Regarding short-term risk, 2526.HK is less volatile compared to 2160.HK. This indicates lower risk in terms of short-term price fluctuations for 2526.HK.Check 2160.HK's competition here
Vincent Medical Holdings Limited (HKSE: 1612.HK)
2526.HK vs 1612.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 1612.HK has a market cap of 432.3M. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 1612.HK trades at HK$0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 1612.HK's P/E ratio is 4.47. In terms of profitability, 2526.HK's ROE is N/A, compared to 1612.HK's ROE of +0.14%. Regarding short-term risk, 2526.HK is more volatile compared to 1612.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 1612.HK's competition here
Cryofocus Medtech (Shanghai) Co. Ltd. (HKSE: 6922.HK)
2526.HK vs 6922.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 6922.HK has a market cap of 400.2M. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 6922.HK trades at HK$2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 6922.HK's P/E ratio is -14.13. In terms of profitability, 2526.HK's ROE is N/A, compared to 6922.HK's ROE of N/A. Regarding short-term risk, 2526.HK is less volatile compared to 6922.HK. This indicates lower risk in terms of short-term price fluctuations for 2526.HK.Check 6922.HK's competition here
Suzhou Basecare Medical Corporation Limited (HKSE: 2170.HK)
2526.HK vs 2170.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2170.HK has a market cap of 377.5M. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2170.HK trades at HK$1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2170.HK's P/E ratio is -1.04. In terms of profitability, 2526.HK's ROE is N/A, compared to 2170.HK's ROE of -0.19%. Regarding short-term risk, 2526.HK is more volatile compared to 2170.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 2170.HK's competition here
Broncus Holding Corporation (HKSE: 2216.HK)
2526.HK vs 2216.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2216.HK has a market cap of 368.6M. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2216.HK trades at HK$0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2216.HK's P/E ratio is -2.20. In terms of profitability, 2526.HK's ROE is N/A, compared to 2216.HK's ROE of -0.12%. Regarding short-term risk, 2526.HK is less volatile compared to 2216.HK. This indicates lower risk in terms of short-term price fluctuations for 2526.HK.Check 2216.HK's competition here
Austar Lifesciences Limited (HKSE: 6118.HK)
2526.HK vs 6118.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 6118.HK has a market cap of 363.9M. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 6118.HK trades at HK$0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 6118.HK's P/E ratio is 21.21. In terms of profitability, 2526.HK's ROE is N/A, compared to 6118.HK's ROE of +0.02%. Regarding short-term risk, 2526.HK is more volatile compared to 6118.HK. This indicates higher risk in terms of short-term price fluctuations for 2526.HK.Check 6118.HK's competition here
Rainmed Medical Limited (HKSE: 2297.HK)
2526.HK vs 2297.HK Comparison September 2026
Hangzhou Diagens Biotechnology Co., Ltd. (HKSE: 2526.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 38.4B. In comparison, 2297.HK has a market cap of 231.2M. Regarding current trading prices, 2526.HK is priced at HK$429.60 on the HKSE, while 2297.HK trades at HK$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -490.91, whereas 2297.HK's P/E ratio is -2.36. In terms of profitability, 2526.HK's ROE is N/A, compared to 2297.HK's ROE of -0.19%. Regarding short-term risk, 2526.HK is less volatile compared to 2297.HK. This indicates lower risk in terms of short-term price fluctuations for 2526.HK.Check 2297.HK's competition here